Four mood stabilizers commonly induce FEZ1 expression in human astrocytes

Bipolar Disorders

Volumn 13, Issue 5-6, 2011, Pages 486-499

  Yu, Zhiqian ^a   Ono, Chiaki ^a   Kim, Helen B ^b   Komatsu, Hiroshi ^a   Tanabe, Yoichiro ^a   Sakae, Nobutaka ^c   Nakayama, Keiichi I ^d   Matsuoka, Hiroo ^a   Sora, Ichiro ^a   Bunney, William E ^b   Tomita, Hiroaki ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c KYUSHU UNIVERSITY   (Japan)

^d KYUSHU UNIVERSITY   (Japan)

Author keywords

Astrocyte; Bipolar disorder; Carbamazepine; FEZ1; Lamotrigine; Lithium; Mood stabilizer; Valproic acid

Indexed keywords

CARBAMAZEPINE; LAMOTRIGINE; LITHIUM; MOOD STABILIZER; VALPROIC ACID;

ARTICLE; ASTROCYTE; BIPOLAR DISORDER; CELL PROTECTION; DRUG MECHANISM; FEZ1 GENE; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANTIMANIC AGENTS; ASTROCYTES; CELL LINE, TRANSFORMED; CLUSTER ANALYSIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NERVE TISSUE PROTEINS; NEURONS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEIN TRANSPORT; TRANSCRIPTION FACTORS;

EID: 80054851572     PISSN: 13985647     EISSN: 13995618     Source Type: Journal    
DOI: 10.1111/j.1399-5618.2011.00946.x     Document Type: Article

References (70)

1. Williams R, Ryves WJ, Dalton EC et al. A molecular cell biology of lithium. Biochem Soc Trans 2004; 32: 799-802.
2. Di Daniel E, Cheng L, Maycox PR, Mudge AW. The common inositol-reversible effect of mood stabilizers on neurons does not involve GSK3 inhibition, myo-inositol-1-phosphate synthase or the sodium-dependent myo-inositol transporters. Mol Cell Neurosci 2006; 32: 27-36.
3. Beaulieu JM, Caron MG. Looking at lithium: molecular moods and complex behaviour. Mol Interv 2008; 8: 230-241.
4. O'Brien WT, Klein PS. Validating GSK3 as an in vivo target of lithium action. Biochem Soc Trans 2009; 37: 1133-1138.
5. Quiroz JA, Gould TD, Manji HK. Molecular effects of lithium. Mol Interv 2004; 4: 259-272.
6. Shaltiel G, Dalton EC, Belmaker RH, Harwood AJ, Agam G. Specificity of mood stabilizer action on neuronal growth cones. Bipolar Disord 2007; 9: 281-289.
7. Leng Y, Liang MH, Ren M, Marinova Z, Leeds P, Chuang DM. Synergistic neuroprotective effects of lithium and valproic acid or other histone deacetylase inhibitors in neurons: roles of glycogen synthase kinase-3 inhibition. J Neurosci 2008; 28: 2576-2588.
8. Du J, Gray NA, Falke C, Yuan P, Szabo S, Manji HK. Structurally dissimilar antimanic agents modulate synaptic plasticity by regulating AMPA glutamate receptor subunit GluR1 synaptic expression. Ann NY Acad Sci 2003; 1003: 378-380.
9. Friedrich MJ. Molecular studies probe bipolar disorder. JAMA 2005; 293: 535-536.
10. Doetsch F, Caillé I, Lim DA, García-Verdugo JM, Alvarez-Buylla A. Subventricular zone astrocytes are neural stem cells in the adult mammalian brain. Cell 1999; 97: 703-716.
11. Hama K, Arii T, Kosaka T. Three-dimensional organization of neuronal and glial processes: high voltage electron microscopy. Microsc Res Tech 1994; 29: 357-367.
12. Haydon PG. GLIA: listening and talking to the synapse. Nat Rev Neurosci 2001; 2: 185-193.
13. Kosaka T, Hama K. Three-dimensional structure of astrocytes in the rat dentate gyrus. J Comp Neurol 1986; 249: 242-260.
14. Ventura R, Harris KM. Three-dimensional relationships between hippocampal synapses and astrocytes. J Neurosci 1999; 19: 6897-6906.
15. Rajkowska G. Cell pathology in bipolar disorder. Bipolar Disord 2002; 4: 105-116.
16. Ongür D, Drevets WC, Price JL. Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc Natl Acad Sci USA 1998; 95: 13290-13295.
17. Rajkowska G, Halaris A, Selemon LD. Reductions in neuronal and glial density characterize the dorsolateral prefrontal cortex in bipolar disorder. Biol Psychiatry 2001; 49: 741-752.
18. Manji HK, Moore GJ, Rajkowska G, Chen G. Neuroplasticity and cellular resilience in mood disorders. Mol Psychiatry 2000; 5: 578-593.
19. Webster MJ, O'Grady J, Kleinman JE, Weickert CS. Glial fibrillary acidic protein mRNA levels in the cingulate cortex of individuals with depression, bipolar disorder and schizophrenia. Neuroscience 2005; 133: 453-461.
20. Johnston-Wilson NL, Sims CD, Hofmann JP et al. Disease-specific alterations in frontal cortex brain proteins in schizophrenia, bipolar disorder, and major depressive disorder. The Stanley Neuropathology Consortium. Mol Psychiatry 2000; 5: 142-149.
21. Andreazza AC, Cassini C, Rosa AR et al. Serum S100B and antioxidant enzymes in bipolar patients. J Psychiatr Res 2007; 41: 523-529.
22. Roche S, Cassidy F, Zhao C et al. Candidate gene analysis of 21q22: support for S100B as a susceptibility gene for bipolar affective disorder with psychosis. Am J Med Genet B Neuropsychiatr Genet 2007; 144B: 1094-1096.
23. Pardo R, Andreolotti AG, Ramos B, Picatoste F, Claro E. Opposed effects of lithium on the MEK-ERK pathway in neural cells: inhibition in astrocytes and stimulation in neurons by GSK3 independent mechanisms. J Neurochem 2003; 87: 417-426.
24. Chen PS, Peng GS, Li G et al. Valproate protects dopaminergic neurons in midbrain neuron/glia cultures by stimulating the release of neurotrophic factors from astrocytes. Mol Psychiatry 2006; 11: 1116-1125.
25. Lubrich B, van Calker D. Inhibition of the high affinity myo-inositol transport system: a common mechanism of action of antibipolar drugs? Neuropsychopharmacology 1999; 21: 519-529.
26. Li B, Zhang S, Li M, Zhang H, Hertz L, Peng L. Down-regulation of GluK2 kainate receptor expression by chronic treatment with mood-stabilizing anti-convulsants or lithium in cultured astrocytes and brain, but not in neurons. Neuropharmacology 2009; 57: 375-385.
27. Li B, Zhang S, Li M, Hertz L, Peng L. Chronic treatment of astrocytes with therapeutically relevant fluoxetine concentrations enhances cPLA2 expression secondary to 5-HT2B-induced, transactivation-mediated ERK1/2 phosphorylation. Psychopharmacology 2009; 207: 1-12.
28. Song D, Du T, Li B et al. Astrocytic alkalinization by therapeutically relevant lithium concentrations: implications for myo-inositol depletion. Psychopharmacology 2008; 200: 187-195.
29. Dahlquist KD, Salomonis N, Vranizan K, Lawlor SC, Conklin BR. GenMAPP, a new tool for viewing and analyzing microarray data on biological pathways. Nat Genet 2002; 31: 19-20.
30. Miller LD, Long PM, Wong L, Mukherjee S, McShane LM, Liu ET. Optimal gene expression analysis by microarrays. Cancer Cell 2002; 2: 353-361.
31. Choe SE, Boutros M, Michelson AM, Church GM, Halfon MS. Preferred analysis methods for Affymetrix GeneChips revealed by a wholly defined control dataset. Genome Biol 2005; 6: R16.
32. Honda A, Miyoshi K, Baba K et al. Expression of fasciculation and elongation protein zeta-1 (FEZ1) in the developing rat brain. Brain Res Mol Brain Res 2004; 122: 89-92.
33. Busa WB, Gimlich RL. Lithium-induced teratogenesis in frog embryos prevented by a polyphosphoinositide cycle intermediate or a diacylglycerol analog. Dev Biol 1989; 132: 315-324.
34. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 2001; 276: 36734-36741.
35. Gurvich N, Berman MG, Wittner BS, Gentleman RC, Klein PS, Green JB. Association of valproate-induced teratogenesis with histone deacetylase inhibition in vivo. FASEB J 2005; 19: 1166-1168.
36. May TW, Rambeck B, Jurgens U. Serum concentrations of lamotrigine in epileptic patients: the influence of dose and comedication. Ther Drug Monit 1996; 18: 523-531.
37. Fraser AD, MacNeil W, Isner AF, Camfield PR. Lamotrigine analysis in serum by high-performance liquid chromatography. Ther Drug Monit 1995; 17: 174-178.
38. Chen G, Huang LD, Jiang YM, Manji HK. The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3. J Neurochem 1999; 72: 1327-1330.
39. De Sarno P, Li X, Jope RS. Regulation of Akt and glycogen synthase kinase-3 beta phosphorylation by sodium valproate and lithium. Neuropharmacology 2002; 43: 1158-1164.
40. Williams RS, Cheng L, Mudge AW, Harwood AJ. A common mechanism of action for three mood-stabilizing drugs. Nature 2002; 417: 292-295.
41. Miyoshi K, Honda A, Baba K et al. Disrupted-In-Schizophrenia 1, a candidate gene for schizophrenia, participates in neurite outgrowth. Mol Psychiatry 2003; 8: 685-694.
42. Bloom L, Horvitz HR. The Caenorhabditis elegans gene unc-76 and its human homologs define a new gene family involved in axonal outgrowth and fasciculation. Proc Natl Acad Sci USA 1997; 94: 3414-3419.
43. Assmann EM, Alborghetti MR, Camargo ME, Kobarg J. FEZ1 dimerization and interaction with transcription regulatory proteins involves its coiled-coil region. J Biol Chem 2006; 281: 9869-9881.
44. Kuroda S, Nakagawa N, Tokunaga C, Tatematsu K, Tanizawa K. Mammalian homologue of the Caenorhabditis elegans UNC-76 protein involved in axonal outgrowth is a protein kinase C zeta-interacting protein. J Cell Biol 1999; 144: 403-411.
45. de Sousa Abreu R, Penalva LO, Marcotte EM, Vogel C. Global signatures of protein and mRNA expression levels. Mol Biosyst 2009; 5: 1512-1526.
46. He J, Liu J, Zhang Z, Sun M, Zhu T, Xia C. Expression of fasciculation and elongation protein zeta-1 (FEZ1) in cultured rat neonatal astrocytes. Mol Cell Biochem 2009; 325: 159-167.
47. Rehli M. Of mice and men: species variations of Toll-like receptor expression. Trends Immunol 2002; 23: 375-378.
48. Rico D, Vaquerizas JM, Dopazo H, Bosca L. Identification of conserved domains in the promoter regions of nitric oxide synthase 2: implications for the species-specific transcription and evolutionary differences. BMC Genomics 2007; 8: 271.
49. Lipska BK, Peters T, Hyde TM et al. Expression of DISC1 binding partners is reduced in schizophrenia and associated with DISC1 SNPs. Hum Mol Genet 2006; 15: 1245-1258.
50. Yamada K, Nakamura K, Minabe Y et al. Association analysis of FEZ1 variants with schizophrenia in Japanese cohorts. Biol Psychiatry 2004; 56: 683-690.
51. Sakae N, Yamasaki N, Kitaichi K et al. Mice lacking the schizophrenia-associated protein FEZ1 manifest hyperactivity and enhanced responsiveness to psychostimulants. Hum Mol Genet 2008; 17: 3191-3203.
52. Cousins DA, Butts K, Young AH. The role of dopamine in bipolar disorder. Bipolar Disord 2009; 11: 787-806.
53. Fujita T, Maturana AD, Ikuta J et al. Axonal guidance protein FEZ1 associates with tubulin and kinesin motor protein to transport mitochondria in neurites of NGF-stimulated PC12 cells. Biochem Biophys Res Commun 2007; 361: 605-610.
54. Ikuta J, Maturana A, Fujita T et al. Fasciculation and elongation protein zeta-1 (FEZ1) participates in the polarization of hippocampal neuron by controlling the mitochondrial motility. Biochem Biophys Res Commun 2007; 353: 127-132.
55. Kato T. The role of mitochondrial dysfunction in bipolar disorder. Drug News Perspect 2006; 19: 597-602.
56. Quiroz JA, Gray NA, Kato T, Manji HK. Mitochondrially mediated plasticity in the pathophysiology and treatment of bipolar disorder. Neuropsychopharmacology 2008; 33: 2551-2565.
57. Auboeuf D, Dowhan DH, Li X et al. CoAA, a nuclear receptor coactivator protein at the interface of transcriptional coactivation and RNA splicing. Mol Cell Biol 2004; 24: 442-453.
58. MacVicar BA, Tse FW, Crichton SA, Kettenmann H. GABA-activated Cl- channels in astrocytes of hippocampal slices. J Neurosci 1989; 9: 3577-3583.
59. Northoff G, Steinke R, Czcervenka C et al. Decreased density of GABA-A receptors in the left sensorimotor cortex in akinetic catatonia: investigation of in vivo benzodiazepine receptor binding. J Neurol Neurosurg Psychiatry 1999; 67: 445-450.
60. Motohashi N. GABA receptor alterations after chronic lithium administration. Comparison with carbamazepine and sodium valproate. Prog Neuropsychopharmacol Biol Psychiatry 1992; 16: 571-579.
61. Yuan PX, Huang LD, Jiang YM, Gutkind JS, Manji HK, Chen G. The mood stabilizer valproic acid activates mitogen-activated protein kinases and promotes neurite growth. J Biol Chem 2001; 276: 31674-31683.
62. Aigner L, Arber S, Kapfhammer JP et al. Overexpression of the neural growth-associated protein GAP-43 induces nerve sprouting in the adult nervous system of transgenic mice. Cell 1995; 83: 269-278.
63. da Cunha A, Vitković L. Regulation of immunoreactive GAP-43 expression in rat cortical macroglia is cell type specific. J Cell Biol 1990; 111: 209-215.
64. Vitković L, Steisslinger HW, Aloyo VJ, Mersel M. The 43-kDa neuronal growth-associated protein (GAP-43) is present in plasma membranes of rat astrocytes. Proc Natl Acad Sci USA 1988; 85: 8296-8300.
65. Yamada K, Goto S, Oyama T, Inoue N, Nagahiro S, Ushio Y. In vivo induction of the growth associated protein GAP43/B-50 in rat astrocytes following transient middle cerebral artery occlusion. Acta Neuropathol 1994; 88: 553-557.
66. Petito CK, Chung M, Halaby IA, Cooper AJ. Influence of the neuronal environment on the pattern of reactive astrocytosis following cerebral ischemia. Prog Brain Res 1992; 94: 381-387.
67. Eastwood SL, Harrison PJ. Synaptic pathology in the anterior cingulate cortex in schizophrenia and mood disorders. A review and a Western blot study of synaptophysin, GAP-43 and the complexins. Brain Res Bull 2001; 55: 569-578.
68. Hrdina P, Faludi G, Li Q et al. Growth-associated protein (GAP-43), its mRNA, and protein kinase C (PKC) isoenzymes in brain regions of depressed suicides. Mol Psychiatry 1998; 3: 411-418.
69. Benes FM, Lim B, Subburaju S. Site-specific regulation of cell cycle and DNA repair in post-mitotic GABA cells in schizophrenic versus bipolars. Proc Natl Acad Sci USA 2009; 106: 11731-11736.
70. Iwamoto K, Kakiuchi C, Bundo M, Ikeda K, Kato T. Molecular characterization of bipolar disorder by comparing gene expression profiles of postmortem brains of major mental disorders. Mol Psychiatry 2004; 9: 406-416.